Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

• Main Authors: Ye Peng (Author), Xiaohui Zeng (Author), Liubao Peng (Author), Qiao Liu (Author), Lidan Yi (Author), Xia Luo (Author), Sini Li (Author), Liting Wang (Author), Shuxia Qin (Author), Xiaomin Wan (Author), Chongqing Tan (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: The ORIENT-32 clinical trial revealed that sintilimab plus bevacizumab biosimilar significantly improved the median progression-free survival and median overall survival (OS) compared with sorafenib. This analysis evaluated the cost-effectiveness of sintilimab plus bevacizumab biosimilar...